Use of PPAR-delta agonists in the treatment of disease
US11931365B2 · kind B2 · utility
0Cited by
39References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 25, 2023 |
| Grant date | Mar 19, 2024 |
| Priority date | — |
| Expiry date | Jan 25, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P21/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein is the use sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.